AU2013326133B2 - Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for IBS - Google Patents

Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for IBS Download PDF

Info

Publication number
AU2013326133B2
AU2013326133B2 AU2013326133A AU2013326133A AU2013326133B2 AU 2013326133 B2 AU2013326133 B2 AU 2013326133B2 AU 2013326133 A AU2013326133 A AU 2013326133A AU 2013326133 A AU2013326133 A AU 2013326133A AU 2013326133 B2 AU2013326133 B2 AU 2013326133B2
Authority
AU
Australia
Prior art keywords
ibs
bacterial antigen
level
antigen antibody
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2013326133A
Other languages
English (en)
Other versions
AU2013326133A1 (en
Inventor
Nicholas Chi-Kwan Ling
Steven LOCKTON
Fred Princen
Sharat Singh
Shui-long WANG
Stefan Westin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2013326133A1 publication Critical patent/AU2013326133A1/en
Application granted granted Critical
Publication of AU2013326133B2 publication Critical patent/AU2013326133B2/en
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. Request for Assignment Assignors: NESTEC S.A.
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2013326133A 2012-10-05 2013-10-01 Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for IBS Expired - Fee Related AU2013326133B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261710574P 2012-10-05 2012-10-05
US61/710,574 2012-10-05
US201361871853P 2013-08-29 2013-08-29
US61/871,853 2013-08-29
PCT/IB2013/059045 WO2014053996A2 (en) 2012-10-05 2013-10-01 Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs

Publications (2)

Publication Number Publication Date
AU2013326133A1 AU2013326133A1 (en) 2015-04-23
AU2013326133B2 true AU2013326133B2 (en) 2019-07-04

Family

ID=49447585

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013326133A Expired - Fee Related AU2013326133B2 (en) 2012-10-05 2013-10-01 Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for IBS

Country Status (9)

Country Link
US (1) US10184940B2 (https=)
EP (1) EP2904395B1 (https=)
JP (1) JP6329553B2 (https=)
CN (1) CN104884959B (https=)
AU (1) AU2013326133B2 (https=)
CA (1) CA2886991A1 (https=)
MX (1) MX360479B (https=)
SG (2) SG11201502641YA (https=)
WO (1) WO2014053996A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720250D0 (en) * 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
BR112015027591A2 (pt) * 2013-05-17 2017-07-25 Basf Se processos para a preparação de um ácido, de um cloreto e de um composto de sulfimina
SG11201509371XA (en) * 2013-05-24 2015-12-30 Nestec Sa Pathway specific markers for diagnosing irritable bowel syndrome
AU2016349703A1 (en) 2015-11-06 2018-11-01 Vetica Labs, Inc. Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals
EP3421616A1 (en) * 2017-06-29 2019-01-02 Tata Consultancy Services Limited Method and system for monitoring the gut health of an individual
AU2018346255A1 (en) * 2017-10-03 2020-04-23 Seres Therapeutics, Inc. Manipulation of tryptamine metabolism
JP6533930B1 (ja) * 2018-08-23 2019-06-26 一般社団法人日本農業フロンティア開発機構 疾病評価指標算出方法、装置、システム、及び、プログラム、並びに、疾病評価指標を算出するためのモデル作成方法。
US11884958B2 (en) 2019-04-30 2024-01-30 Mayo Foundation For Medical Education And Research Assessing and treating functional gastrointestinal disorders
WO2025071560A1 (en) * 2023-09-28 2025-04-03 Rutgers, The State University Of New Jersey Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048600A2 (en) * 2002-11-22 2004-06-10 Emory University Diagnostic tests and methods for diagnosing inflammatory bowel disease
US20060154276A1 (en) * 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7943328B1 (en) * 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
CN102480932B (zh) * 2009-09-01 2015-01-14 阿昂梅迪克斯公司 源于肠道共生细菌的细胞外小泡及利用其的疫苗、备选药物筛选方法
PH12012500850A1 (en) * 2009-10-30 2013-01-07 Prometheus Laboratories Inc Methods for diagnosing irritable bowel syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome

Also Published As

Publication number Publication date
CA2886991A1 (en) 2014-04-10
CN104884959B (zh) 2017-12-01
JP2015533213A (ja) 2015-11-19
MX2015004271A (es) 2015-08-14
JP6329553B2 (ja) 2018-05-23
WO2014053996A3 (en) 2014-05-30
EP2904395A2 (en) 2015-08-12
US20150346200A1 (en) 2015-12-03
WO2014053996A2 (en) 2014-04-10
CN104884959A (zh) 2015-09-02
SG10201702773QA (en) 2017-06-29
HK1213050A1 (en) 2016-06-24
EP2904395B1 (en) 2018-09-05
MX360479B (es) 2018-11-05
AU2013326133A1 (en) 2015-04-23
US10184940B2 (en) 2019-01-22
SG11201502641YA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
AU2013326133B2 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for IBS
CN105579852B (zh) 用于诊断肠易激惹综合征的途径特异性标志物
US20120276059A1 (en) Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease
AU2011202664B2 (en) Methods for diagnosis and treatment of Crohn's disease
US10295535B2 (en) Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with clostridium difficile disease and differentiating carrier state from active disease
HK1213050B (en) Antibodies to microbiome as diagnostic markers for ibs
CN105242045A (zh) 胃泌素-17作为具有增加的数种相关后发病风险的萎缩性胃炎的生物标志物的用途
JP7740807B2 (ja) 敗血症原因細菌の免疫学的分析方法及び該方法に用いるモノクローナル抗体
JP2024522606A (ja) 機能性消化管障害のための診断マーカー
NZ701004B2 (en) Clostridium difficile dehydrogenase and toxin as a biomarker

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER APPLICANT(S): NESTEC S.A.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application